Cargando…
Rationale for azithromycin in COVID-19: an overview of existing evidence
Azithromycin has rapidly been adopted as a repurposed drug for the treatment of COVID-19, despite the lack of high-quality evidence. In this review, we critically appraise the current pharmacological, preclinical and clinical data of azithromycin for treating COVID-19. Interest in azithromycin has b...
Autores principales: | Gyselinck, Iwein, Janssens, Wim, Verhamme, Peter, Vos, Robin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811960/ https://www.ncbi.nlm.nih.gov/pubmed/33441373 http://dx.doi.org/10.1136/bmjresp-2020-000806 |
Ejemplares similares
-
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial
por: Gyselinck, Iwein, et al.
Publicado: (2021) -
Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial
por: Gyselinck, Iwein, et al.
Publicado: (2021) -
Predicting death from COVID-19 using pre-existing conditions: implications for vaccination triage
por: Xiao, Shujie, et al.
Publicado: (2021) -
Remdesivir, on the road to DisCoVeRy
por: Gyselinck, Iwein, et al.
Publicado: (2022) -
Impact of the COVID-19 pandemic on non-COVID-19 community-acquired pneumonia: a retrospective cohort study
por: Lee, Terry, et al.
Publicado: (2023)